

BIBLIOGRAFÍA

Recopilación de las referencias bibliográficas de todos los artículos.

INSUFICIENCIA CARDÍACA Y DIABETES MELLITUS

1. Tancredi M, Rosengren A, Svensson AM, Kosiborod M, Pivodic A, Gudbj S, et al. Excess mortality among persons with type 2 diabetes. *N Engl J Med* 2015;373:18.
2. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. *Diabetes Care* 2001;24(9):1614-9.
3. American Diabetes Association. Standards of medical care in diabetes-2016. *Diabetes Care* 2016;39(Supl 1):S1-2.
4. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al.; Authors/Task Force Members. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2016;37(27):2129-200.
5. From AM, Scott CG, Chen HH. The development of heart failure in patients with diabetes and pre-clinical diastolic dysfunction: a population-based study. *J Am Coll Cardiol* 2010;55(4):300-5.
6. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al.; EMPA-REG Outcome Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med* 2015;373(22): 2117-28.

LA DIETA MEDITERRÁNEA EN LA PERSONA CON DIABETES

- Díaz-López A, Babio N, Martínez-González MA, Corella D, Amor AJ, Fitó M, et al.; PREDIMED Study Investigators. Mediterranean Diet, Retinopathy, Nephropathy, and Microvascular Diabetes Complications: A Post Hoc Analysis of a Randomized Trial. *Diabetes Care* 2015;38(11):2134-41.
- Elhayany A, Lustman A, Abel R, Attal-Singer J, Vinker S. A low carbohydrate Mediterranean diet improves cardiovascular risk factors and diabetes control among overweight patients with type 2 diabetes mellitus: a 1-year prospective randomized intervention study. *Diabetes Obes Metab* 2010;12:204-9.
- Esposito K, Maiorino MI, Bellastella G, Chiodini P, Panagiotakos D, Giugliano D. A journey into a Mediterranean diet and type 2 diabetes: a systematic review with meta-analyses. *BMJ Open* 2015;5(8):e008222.
- Esposito K, Maiorino MI, Ciotola M, Di Palo C, Scognamiglio P, Gicchino M, et al. Effects of a Mediterranean-style diet on the need for antihyperglycemic drug therapy in patients

with newly diagnosed type 2 diabetes: a randomized trial. *Ann Intern Med* 2009;151:306-14.

- Esposito K, Maiorino MI, Petrizzo M, Bellastella G, Giugliano D. The effects of a Mediterranean diet on the need for diabetes drugs and remission of newly diagnosed type 2 diabetes: follow-up of a randomized trial. *Diabetes Care* 2014;37(7):1824-30.
- Estruch R, Martínez-González MA, Corella D, Salas-Salvadó J, Fitó M, Chiva-Blanch G, et al. PREDIMED Study Investigators. Effect of a high-fat Mediterranean diet on bodyweight and waist circumference: a prespecified secondary outcomes analysis of the PREDIMED randomised controlled trial. *Lancet Diabetes Endocrinol* 2016;4(8):666-76.
- Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, et al. PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. *N Engl J Med* 2013;368(14):1279-90.
- Franz MJ, Boucher JL, Rutten-Ramos S, VanWormer JJ. Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. *J Acad Nutr Diet* 2015;115:1447-63.
- Huo R, Du T, Xu Y, Xu W, Chen X, Sun K, et al. Effects of Mediterranean-style diet on glycemic control, weight loss and cardiovascular risk factors among type 2 diabetes individuals: a meta-analysis. *Eur J Clin Nutr* 2015;69:1200-8.
- Ortega E, Franch J, Castell C, Goday A, Ribas-Barba L, Sorribes F, et al. Mediterranean diet adherence in individuals with prediabetes and unknown diabetes: the Di@bet.es Study. *Ann Nutr Metab* 2013;62(4):339-46.
- Ryan MC, Itsopoulos C, Thodis T, Ward G, Trost N, Hofferberth S, et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. *J Hepatol* 2013;59(1):138-43.
- Toobert DJ, Glasgow RE, Strycker LA, Barrera M Jr, Radcliffe JL, Wander RC, et al. Biologic and quality-of-life outcomes from the Mediterranean Lifestyle Program: a randomized clinical trial. *Diabetes Care* 2003;26:2288-93.

SEGUIMIENTO DE LAS COHORTES DEL ESTUDIO PREDAPS

1. Heianza Y, Hara S, Arase Y, Saito K, Fujiwara K, Tsuji H, et al. HbA1c 5.7-6.4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study. *Lancet* 2011;378:147-55.
2. Inoue K, Matsumoto M, Akimoto K. Fasting plasma glucose and HbA1c as risk factors for type 2 diabetes. *Diabet Med* 2008;25:1157-63.
3. Gerstein HC, Santaguida P, Raina P, Morrison KM, Balion C, Hunt D, et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. *Diabetes Res Clin Pract* 2007;78:305-12.

4. Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk state for diabetes development. *Lancet* 2012;379:2279-90.
5. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 2002;346:393-403.
6. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hääläinen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med* 2001;344:1343-50.
7. Costa B, Barrio F, Cabré J-J, Piñol J-L, Cos X, Solé C, et al. Delaying progression to type 2 diabetes among high-risk Spanish individuals is feasible in real-life primary healthcare settings using intensive lifestyle intervention. *Diabetologia* 2012;55:1319-28.
8. Serrano R, García-Soidán FJ, Díaz-Redondo A, Artola S, Franch J, Díez J, et al. Estudio de cohortes en atención primaria sobre la evolución de sujetos con prediabetes (PREDAPS): fundamentos y metodología. *Rev Esp Salud Pública* 2013;87:121-35.
9. García-Soidán FJ, Serrano Martín R, Díaz-Redondo A, Artola Menéndez S, Franch Nadal J, Díez J, et al. Evolución de pacientes con prediabetes en atención primaria de salud (PREDAPS): resultados de la etapa basal. *Diabetes Práctica* 2013;(Supl 4):S1-32.
10. Colaguri S. Epidemiology of prediabetes. *Med Clin North Am* 2011;95:299-307.
11. Mann DM, Carson AP, Shimbo D, Fonseca V, Fox CS, Muntner P. Impact of A1C screening criterion on the diagnosis of prediabetes among U.S. adults. *Diabetes Care* 2010;33:2190-5.
12. Zhang YH, Ma WJ, Thomas GN, Xu YJ, Lao XQ, Xu XJ, et al. Diabetes and pre-diabetes as determined by glycated haemoglobin A1c and glucose levels in a developing southern Chinese population. *PLoS One* 2012;7:e37260.
13. Díaz-Redondo A, Giráldez-García C, Carrillo L, Serrano R, García-Soidán FJ, Artola S, et al. Modifiable risk factors associated with prediabetes in men and women: a cross-sectional analysis of the cohort study in primary health care on the evolution of patients with prediabetes (PREDAPS-Study). *BMC Fam Pract* 2015;16:5.
14. Giráldez-García C, Sangrós FJ, Díaz-Redondo A, Franch-Nadal J, Serrano R, Díez J, et al.; PREDAPS Study Group. Cardiometabolic Risk Profiles in Patients With Impaired Fasting Glucose and/or Hemoglobin A1c 5.7% to 6.4%: Evidence for a Gradient According to Diagnostic Criteria: the PREDAPS Study. *Medicine (Baltimore)* 2015;94:e1935.
15. Giráldez-García C, Paniagua F, Sanz G, Alonso M, Colás R, Ortega FJ, et al.; en nombre del Grupo de Estudio PREDADS. Evolución de pacientes con prediabetes en Atención Primaria de Salud (PREDAPS): resultados del tercer año de seguimiento. *Diabetes Práctica* 2016;07:61-76.
16. Yudkin JS, Montori VM. The epidemic of pre-diabetes: the medicine and the politics. *BMJ* 2014;349:g4485.
17. Van den Bruel A. The triumph of medicine: how overdiagnosis is turning healthy people into patients. *Fam Pract* 2015;32:127-8.
18. Yudkin JS. «Prediabetes»: are there problems with this label? Yes, the label creates further problems! *Diabetes Care* 2016;39:1468-71.
19. Cefalu WT. «Prediabetes»: are there problems with this label? No, we need heightened awareness of this condition! *Diabetes Care* 2016;39:1472-7.
20. Bullard KM, Saydah SH, Imperatore G, Cowie CC, Gregg EW, Geiss LS, et al. Secular changes in U.S. Prediabetes prevalence defined by hemoglobin A1c and fasting plasma glucose: National Health and Nutrition Examination Surveys, 1999-2010. *Diabetes Care* 2013;36:2286-93.
21. Gil-Montalbán E, Martín-Ríos MD, Ortiz-Marrón H, Zorrilla-Torras B, Martínez-Cortés M, Esteban-Vasallo MD, et al. Incidence of type 2 diabetes and associated factors in the adult population of the Community of Madrid. PREDIMERC cohort. *Rev Clin Esp* 2015;215:495-502.
22. Baena-Díez JM, Bermúdez-Chillida N, Mundet X, Del Val-García JL, Muñoz MA, Schröder H. Glicemia basal alterada y riesgo de diabetes mellitus a los 10 años: estudio de cohorte. *Med Clin Barc* 2011;136:382-5.

HÍGADO GRASO NO ALCOHÓLICO Y DIABETES

- Adams LA, Waters OR, Knuiman MW, Elliot RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. *Am J Gastroenterol* 2009;104:861-7.
- Armstrong MJ, Houlihan DD, Rowe IA, Clausen VH, Elbrond B, Gough SC, et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program. *Aliment Pharmacol Ther* 2013;37:234-42.
- Anstee QM, Day CP. The genetics of NAFLD. *Nat Rev Gastroenterol Hepatol* 2013;10:645-55.
- Arase Y, Kawamura Y, Seko Y, Kobayashi M, Suzuki F, Suzuki Y, et al. Efficacy and safety of sitagliptin therapy for diabetes complicated with non-alcoholic fatty liver disease. *Hepatol Res* 2013;43:1163-8.
- Armstrong MJ, Hazlehurst JM, Parker R, Koushiappi E, Mann J, Khan S, et al. Severe asymptomatic non-alcoholic fatty liver disease in routine diabetes care: a multidisciplinary team approach. *QJM* 2014;107:33-41.
- Bhatt HB, Smith RJ. Fatty liver disease in diabetes mellitus. *Hepato Biliary Surg Nutr* 2015;4:101-8.
- Caballería L, Pera G, Auladell MA, Torán P, Muñoz L, Miranda D, et al. Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain. *Eur J Gastroenterol Hepatol* 2010;22:24-32.

- Caballería L, Saló J, Berzigotti A, Planas R, Vila C, Huertas C, et al. Hígado graso no alcohólico. Documento de posicionamiento de la Sociedad Catalana de Digestología. *Gastroenterol Hepatol* 2014;37:372-83.
- Chalasani N, Younossi Z, Lavine JE, Diehk AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practical guide-line by the American Association for the Study of Liver Diseases, American College of Gastroenterology and the American Gastroenterological Association. *Hepatology* 2012;55:2005-23.
- EASL-EASD-EASO. Clinical practice guidelines for the management of non-alcoholic fatty liver disease. *Diabetologia* 2016;59:1121-40.
- Gawrieh S, Chalasani N. Pharmacotherapy for nonalcoholic fatty liver disease. *Sem Liver Dis* 2015;35:338-48.
- Hazlehurst JM, Woods C, Marjot T, Cobbold JF, Tomlinson JW. Non-alcoholic fatty liver disease and diabetes. *Metabolism* 2016;65(8):1096-108.
- Loria P, Lonardo A, Anania F. Liver and diabetes a vicious circle. *Hepatol Res* 2013;43:51-64.
- Pappachan JM, Antonio FA, Edavalath M, Mukherjee A. Nonalcoholic fatty liver disease: a diabetologist's perspective. *Endocrine* 2014;45:344-53.
- Portillo-Sánchez P, Bril F, Maximos M, Lomonaco R, Biernacki D, Orsak B, et al. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. *J Clin Endocrinol Metab* 2015;100:2231-8.
- Rinella ME, Sanyal AJ. Management of NAFLD: a stage-based approach. *Nat Rev Gastroenterol Hepatol* 2016;13:196-205.
- Saponaro C, Gaggini M, Gastaldelli A. Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms. *Curr Diab Rep* 2015;15:607.
- Satapathy SK, Sanyal AJ. Epidemiology and natural history of nonalcoholic fatty liver disease. *Sem Liver Dis* 2015;35:221-35.
- Targher G, Bertolini L, Chonchol M, Rodella S, Zoppini G, Lippi G, et al. Nonalcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients. *Diabetologia* 2010;53:1341-8.
- Targher G, Bertolini L, Rodella S, Tessari R, Zenari L, Lippi G, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. *Diabetes Care* 2007;30:2119-21.
- DeFronzo RA, Abdul-Ghani M. Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. *Am J Cardiol* 2011;108:3B-24B.
- Reddy MA, Zhang E, Natarajan R. Epigenetic mechanisms in diabetic complications and metabolic memory. *Diabetologia* 2015;58:443-55.
- Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hääläinen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med* 2001;344:1343-50.
- Flórez JC. Genetic susceptibility to type 2 diabetes and implications for therapy. *J Diabetes Sci Technol* 2009;3:690-6.
- Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. *Cell Res* 2008;18:997-1006.
- Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. *Nat Cell Biol* 2011;13:423-33.
- Díaz-Redondo A, Giráldez-García C, Carrillo L, Serrano R, García-Soidán FJ, Artola S, et al. Modifiable risk factors associated with prediabetes in men and women: a cross-sectional analysis of the cohort study in primary health care on the evolution of patients with prediabetes (PREDAPS-Study). *BMC Fam Pract* 2015;16:5.
- Giráldez-García C, Sangros FJ, Díaz-Redondo A, Franch-Nadal J, Serrano R, Díez J, et al. Cardiometabolic risk profiles in patients with impaired fasting glucose and/or hemoglobin A1c 5.7% to 6.4%: evidence for a gradient according to diagnostic criteria: the PREDAPS Study. *Medicine (Baltimore)* 2015;94:e1935.
- Párrizas M, Brugnara L, Esteban Y, González-Franquesa A, Canivell S, Murillo S, et al. Circulating miR-192 and miR-193b are markers of prediabetes and are modulated by an exercise intervention. *J Clin Endocrinol Metab* 2015;100:E407-15.
- Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 2001;25:402-8.
- Sung K-C, Wild SH, Byrne CD. Resolution of fatty liver and risk of incident diabetes. *J Clin Endocrinol Metab* 2013;98:3637-43.
- Bedogni G, Kahn HS, Bellentani S, Tiribelli C. A simple index of lipid overaccumulation is a good marker of liver steatosis. *BMC Gastroenterol* 2010;10:98.

NUEVOS BIOMARCADORES EPIGENÉTICOS PARA LA DIABETES: MICROÁCIDOS RIBONUCLEICOS CIRCULANTES EN EL ESTUDIO PREDAPS

1. Groop L, Pociot F. Genetics of diabetes--are we missing the genes or the disease? *Mol Cell Endocrinol* 2014;382:726-39.

ENFERMEDAD RENAL DIABÉTICA

1. Martín de Francisco AL, Piñera C, Gago M, Ruiz J, Robledo C, Arias M, et al. Epidemiología de la enfermedad renal crónica en pacientes no nefrológicos. *Nefrologia* 2009;29:101-5.

2. Rodríguez-Poncelas A, Garre J, Franch J, Diez-Espino J, Mundet-Tuduri X, Barrot-De la Puente J, et al.; RedGDPS Study Group. Prevalence of chronic kidney disease in patients with type 2 diabetes in Spain: PERCEDIME2 study. *BMC Nephrol* 2013;14:46-52.
3. Levey AS, Stevens LA, Coresh J. Conceptual model of CKD: applications and implications. *Am J Kidney Dis* 2009;53(3 Suppl 3):S4-16.
4. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. *Kidney Int Suppl* 2012;2:337-414.
5. Garg R, Williams ME. Diabetes management in the kidney patient. *Med Clin North Am* 2013;97:135-56.
6. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. *N Engl J Med* 2016;375:323-34.